AI across the pharma value chain

We'll take each in turn, separating what works from what is oversold.

AI in drug discovery

Where it adds real value

Target identification. Before you design a drug, you need a biological "target," usually a protein involved in a disease. AI models trained on genomics, scientific literature, and lab data help rank which targets are most promising. This narrows a huge search space.

Molecule generation and screening. "Generative chemistry" models propose new molecular structures with desired properties (binds the target, is stable, is not toxic). Instead of physically testing millions of compounds, teams use models to prioritize the few thousand worth making in a lab. This is *virtual screening*, and it genuinely compresses early timelines.

Structure prediction. AlphaFold and its successors let chemists see how a molecule might fit into a target protein's binding pocket. You can explore the free AlphaFold Protein Structure Database directly.

Where hype outruns reality

Here is the crucial caveat: predicting a molecule looks promising is not the same as having a drug.

Several AI-native biotech companies have advanced candidates into human trials in recent years, and a few have reported clinical setbacks. As of 2026, no drug discovered primarily by AI has completed the full journey to broad regulatory approval and market. That does not mean AI failed. It means the hard part, human biology, remains stubborn. A molecule that binds beautifully in a simulation can still be toxic, get cleared by the body too fast, or simply not work in a real patient.

The bottleneck moved, it did not disappear. AI makes the *early* funnelfunnelThe customer journey from awareness to purchase, typically Awareness, Interest, Consideration, Decision, Action, with prospects narrowing at each stage.Voir la définition complète → faster and cheaper. But roughly 90% of drugs that enter clinical trials still fail, and AI has not yet changed that late-stage attrition rateattrition rateChurn rate is the percentage of customers or revenue lost over a period. It measures how fast a business loses its existing customer base.Voir la définition complète → in any proven way. If a vendor promises AI will "solve" clinical failure, be skeptical.

AI in clinical development

The clinic is where most cost and most failure live. This is why optimizing trials may be the higher-value application, even if discovery gets the headlines.

Trial design and simulation

Designing a trial means choosing the dose, the patient population, the endpoints (the measurable outcomes that define success), and the sample size. Get these wrong and you burn years.

AI helps in concrete ways:

• Site and enrollment forecasting: predicting which hospitals will actually recruit patients on time. Slow enrollment is a leading cause of trial delays.
• Synthetic control arms: using historical patient data to model a comparison group, reducing the number of patients who must receive a placebo. Regulators are cautious here, but interested.
• Protocol optimization: flagging overly complex protocols that will exhaust patients and staff.

Patient identification and recruitment

AI models scan de-identified electronic health records to find patients who match strict eligibility criteria. For a rare disease trial, finding 40 qualifying patients across a continent is a genuine needle-in-haystack problem, and this is a real, deployed use case.

Monitoring and safety

During a trial, AI flags anomalies in incoming data (a site reporting suspiciously clean numbers, an adverse event pattern worth investigating). This supports pharmacovigilance, the ongoing monitoring of drug safety, which continues long after approval.

The regulatory reality

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both now engage actively with AI in drug development. The FDA has published a framework for evaluating AI used to support regulatory decisions about drug safety and effectiveness. The direction is clear: AI is welcome as a tool, but the sponsor must be able to explain and justify how the model was used. "The algorithm said so" is not an acceptable submission.

If you want the primary source, the FDA maintains a public page on Artificial Intelligence in Drug Development.

A simple way to evaluate an AI claim

When someone pitches you an AI pharma investment, the failure mode is confusing *speed in the cheap early stages* with *success in the expensive late stages*. Use a rough mental model of value:

Expected value of an AI application =
   (time or cost saved at that step)
 × (how often that step is the real bottleneck)
 × (whether the output is trusted by scientists AND regulators)

Apply it:

• Generative chemistry scores high on cost saved, but the output still faces the full clinical gauntlet. High value, but not a shortcut to approval.
• Enrollment forecasting saves time at a step that genuinely delays most trials, and regulators do not need to bless the forecast itself. Quietly excellent value.
• A chatbot that "reads all the literature" may save analyst hours but rarely sits on the critical path. Useful, not transformative.

The unglamorous operational applications often beat the headline-grabbing discovery ones on this math.

Data: the real constraint

None of this works without data, and pharma data is messy. Discovery models need high-quality experimental results, including the failures (which companies rarely publish). Clinical models need patient data that is fragmented across hospitals, coded inconsistently, and tightly regulated for privacy.

Two practical consequences:

1. Proprietary data is the moat. A company's own decades of screening results or trial records are often more valuable than the model architecture, which is increasingly commoditized.

2. Garbage in, garbage out is not a cliché here. A model trained on biased or incomplete patient data can produce a candidate or a trial design that fails in populations it never saw. This is both a scientific and an ethical risk.

Where to place your bets in 2026

For a professional deciding where to invest, the landscape looks like this:

• Discovery AI is real and improving, but returns are long-dated and unproven at the finish line. Treat claims of imminent "AI-designed blockbusters" as unvalidated until a drug clears late-stage trials and approval.
• Clinical operations AI (recruitment, monitoring, forecasting) offers nearer-term, measurable savings and faces lower regulatory hurdles because it supports human decisions rather than replacing evidence.
• Data infrastructure underpins everything and is often the most durable asset.

This is analysis, not investment or medical advice. Every therapy area and company differs, and clinical outcomes are inherently uncertain.

Key Takeaways

• AI genuinely compresses the early, cheap end of pharma (target selection, molecule generation, structure prediction), but late-stage clinical failure remains the dominant cost and AI has not yet proven it can reduce it.
• As of 2026, no AI-discovered drug has completed the full path to broad approval. Promising simulations are not approved medicines. Discount pitches that blur this line.
• The quietly high-value applications are often operational: patient recruitment, enrollment forecasting, and safety monitoring save time at real bottlenecks with lower regulatory risk.
• Regulators (FDA, EMA) accept AI as a tool but demand explainability. A model's output must be justified, not just presented.
• Proprietary, high-quality data is the real moat, and biased or incomplete data is a genuine scientific and ethical risk, not a footnote.